Drug combination improves progression-free survival in patients with renal cell carcinoma
Renal cell carcinoma (RCC) tumors generally display specific genetic alterations that cause cancer cells to increase the metabolism of glutamine. Dual targeting of glucose and glutamine metabolism by the mTOR inhibitor everolimus, plus the glutaminase inhibitor telaglenastat, showed preclinical synergistic anticancer effects. The Phase II ENTRATA study, led by Nizar Tannir, M.D., enrolled 69 patients with a median of three prior lines of therapy for advanced metastatic disease, including 100% with two or more prior...